Tag Archive for: men’s health

Futura Medical extends collaboration with Cooper Consumer Health

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise Eroxon®, the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment, throughout the European […]

Read more

Futura Medical plc – Appointment of Roy Davis as Non-Executive Director

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces the appointment of Roy Davis as a Non-Executive Director with immediate effect. Read more…

Read more

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, is pleased to announce that M8 Pharmaceuticals, Inc (“M8”) has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further fourteen countries throughout the Central and South American region. Read more…

Read more

Futura Medical – MED3000 approved for Commercialisation in Saudi Arabia under the brand name Eroxon®

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology, today announces that its distribution partner Labatec Pharma (“Labatec”) has received regulatory approval for MED3000, Futura’s innovative topical, gel-based Erectile Dysfunction (“ED”) treatment, in the Kingdom of Saudi Arabia. Read more…

Read more

Futura Medical Announces Agreement With Haleon To Commercialise MED3000 In The USA

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, focused on sexual health, today announces that it has entered into a ground breaking licensing agreement with Haleon plc (“Haleon”), a world leading consumer healthcare Company for the rights to […]

Read more